Lixisenatide: difference between revisions
Diff·revision 15 → 16·22:14, 13 Aug 2025
Difference between revision 15 and revision 16 of Lixisenatide. 2 lines changed; the page grew by 138 bytes.
| Revision 15 — 03:52, 20 Jul 2025 Hedgerow_Hal (talk) give the isoelectric point with the method it was determined by 4,057 bytes ±0 | Revision 16 — 22:14, 13 Aug 2025 CagriCass (talk) rm a duplicated category 4,195 bytes +138 | ||
|---|---|---|---|
| 33 | It is not commonly encountered in research-chemical supply relative to the weekly analogues, which reflects demand rather than any property of the molecule.{{r|reports}} As a 44-residue exendin derivative it presents the ordinary synthetic-peptide characterisation problem.{{r|usp1503}} | 33 | It is not commonly encountered in research-chemical supply relative to the weekly analogues, which reflects demand rather than any property of the molecule.{{r|reports}} As a 44-residue exendin derivative it presents the ordinary synthetic-peptide characterisation problem.{{r|usp1503}} |
| 34 | 34 | ||
| + | 35 | Its lasting significance is evidential: it is the clearest single counter-example to a class-wide cardiovascular claim.{{r|pfeffer2015}} | |
| + | 36 | ||
| 35 | == References == | 37 | == References == |
| 36 | {{reflist}} | 38 | {{reflist}} |